Craniopharyngioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRN036 MIFTS: 68	Craniopharyngioma Categories: Cancer diseases, Endocrine diseases, Eye diseases, Fetal diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Craniopharyngioma

MalaCards integrated aliases for Craniopharyngioma:

Name: Craniopharyngioma ¹² ⁵⁴ ⁶⁰ ⁵⁶ ⁶ ⁴⁵ ¹⁵ ¹⁷ ⁷⁴

Dysodontogenic Epithelial Tumor ⁵⁴

Craniopharyngeal Duct Tumor ⁵⁴

Neoplasm of Rathke's Pouch ¹²

Adamantinomatous Tumor ⁵⁴

Rathke's Pouch Tumor ⁵⁴

Characteristics:

Orphanet epidemiological data:

⁶⁰

craniopharyngioma
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (United States),1-9/1000000 (Sweden); Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Fetal diseases
Anatomical: Neuronal diseases Endocrine diseases Eye diseases

See all MalaCards categories (disease lists)

ICD10: ³⁵

Neoplasms

Neoplasms of uncertain or unknown behaviour

Neoplasm of uncertain or unknown behaviour of endocrine glands

Neoplasm of uncertain or unknown behaviour: Craniopharyngeal duct

Orphanet: ⁶⁰

Rare neurological diseases

Rare endocrine diseases

External Ids:

Disease Ontology ¹² DOID:3840

MeSH ⁴⁵ D003397

NCIt ⁵¹ C2964

SNOMED-CT ⁶⁹ 40009002

MESH via Orphanet ⁴⁶ D003397

ICD10 via Orphanet ³⁵ D44.4

UMLS via Orphanet ⁷⁵ C0010276

Orphanet ⁶⁰ ORPHA54595

SNOMED-CT via HPO ⁷⁰ 103276001 123526007 128613002 more

EFO ¹⁷ EFO_1000209

UMLS ⁷⁴ C0010276

Sources

Summaries for Craniopharyngioma

NIH Rare Diseases : ⁵⁴ Craniopharyngioma is a slow-growing, non-cancerous brain tumor that develops near the pituitary gland (a small endocrine gland at the base of the brain which produces several important hormones) and the hypothalamus (an endocrine organ which controls the release of hormones by the pituitary gland). This tumor most commonly affects children between 5 and 10 years of age; however, adults can sometimes be affected. Although craniopharyngiomas are not cancerous, they may grow and press on nearby parts of the brain, causing symptoms including hormonal changes, vision changes, slow growth, headaches, nausea and vomiting, loss of balance, hearing loss, and changes in mood or behavior. The cause of these tumors is not well understood; however, researchers suspect that they begin to form during the early stages of embryo development in pregnancy (embryogenesis) and may result from metaplasia (abnormal transformation of cells). Treatment for craniopharyngioma varies and may involve surgery to remove the tumor, radiation therapy, chemotherapy, biologic therapy, and/or hormone therapy to replace various hormones no longer produced or secreted due to the tumor or its treatment.

MalaCards based summary : Craniopharyngioma, also known as dysodontogenic epithelial tumor, is related to papillary craniopharyngioma and familial adenomatous polyposis 1, and has symptoms including visual disturbance An important gene associated with Craniopharyngioma is CTNNB1 (Catenin Beta 1), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Pathways in cancer. The drugs Hydrocortisone acetate and Hydrocortisone have been mentioned in the context of this disorder. Affiliated tissues include brain, pituitary and hypothalamus, and related phenotypes are abnormal hypothalamus morphology and cerebral calcification

Wikipedia : ⁷⁷ Craniopharyngioma is a rare type of brain tumor derived from pituitary gland embryonic tissue that... more...

Sources

Related Diseases for Craniopharyngioma

Diseases related to Craniopharyngioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 273)

#	Related Disease	Score	Top Affiliating Genes
1	papillary craniopharyngioma	34.2	BRAF CTNNB1 KRT7
2	familial adenomatous polyposis 1	30.4	APC CTNNB1
3	galactorrhea	30.2	IGF1 PRL
4	growth hormone deficiency	30.2	GH1 GHRL IGF1
5	ameloblastoma	30.1	KRT14 KRT8 MMP20
6	amenorrhea	29.9	GNRH1 PRL TRH
7	hypogonadotropism	29.9	GNRH1 PRL
8	adenoma	29.7	APC BRAF CTNNB1 GH1 IGF1 PRL
9	anorexia nervosa	29.5	GH1 GHRL IGF1 PRL
10	functioning pituitary adenoma	29.4	GH1 PRL TRH
11	hypothalamic disease	29.4	GH1 GNRH1 PRL
12	hyperprolactinemia	29.3	GH1 GNRH1 IGF1 PRL TRH
13	adenocarcinoma	29.3	APC BRAF CTNNB1 EPCAM VEGFA
14	prader-willi syndrome	29.2	GH1 GHRL GNRH1 IGF1 INS
15	insulin-like growth factor i	29.2	GH1 IGF1 INS PRL
16	chromophobe adenoma	29.1	GH1 GNRH1 INS PRL TRH
17	acromegaly	29.0	GH1 GHRL IGF1 INS PRL TRH
18	hyperthyroidism	28.9	GH1 GHRL INS PRL TRH
19	pituitary hormone deficiency, combined, 2	28.7	GH1 IGF1 POU1F1 PRL PROP1
20	hypopituitarism	28.6	GH1 GNRH1 IGF1 INS POU1F1 PRL
21	pituitary tumors	28.4	GH1 IGF1 POU1F1 PRL PROP1 VEGFA
22	hypothyroidism	28.2	GH1 IGF1 POU1F1 PRL PROP1 TRH
23	pituitary gland disease	27.9	GH1 GNRH1 IGF1 INS POU1F1 PRL
24	adamantinous craniopharyngioma	12.3
25	cystadenoma	11.7
26	proliferating trichilemmal cyst	10.5	KRT7 KRT8
27	endolymphatic sac tumor	10.5	KRT7 KRT8
28	benign breast adenomyoepithelioma	10.4	KRT14 KRT7
29	childhood hepatocellular carcinoma	10.4	CTNNB1 EPCAM
30	hypothalamic obesity	10.4
31	apocrine sweat gland neoplasm	10.4	KRT14 KRT7 KRT8
32	large intestine adenocarcinoma	10.4	CTNNB1 KRT7
33	brooke-spiegler syndrome	10.4	KRT14 KRT7 KRT8
34	lung acinar adenocarcinoma	10.4	CTNNB1 KRT7
35	pregnancy adenoma	10.4	KRT14 KRT7 KRT8
36	basaloid squamous cell carcinoma	10.4	KRT14 KRT7 KRT8
37	intraneural perineurioma	10.4	KRT14 KRT7 KRT8
38	primary cutaneous amyloidosis	10.4	KRT14 KRT7 KRT8
39	oncocytic breast carcinoma	10.4	KRT14 KRT7
40	secondary adrenal insufficiency	10.4	IGF1 INS
41	sweat gland cancer	10.4	KRT14 KRT7 KRT8
42	sarcoma, synovial	10.4	CTNNB1 KRT7 KRT8
43	cervical squamous cell carcinoma	10.3	CTNNB1 KRT8 MKI67
44	breast fibroadenoma	10.3	KRT14 KRT8 MKI67
45	hidrocystoma	10.3	KRT7 KRT8
46	ductal carcinoma in situ	10.3	KRT14 KRT8 MKI67
47	gastrointestinal system benign neoplasm	10.3	CTNNB1 INS KRT7
48	pituitary adenoma	10.3
49	papillary thyroid microcarcinoma	10.3	BRAF EPCAM MKI67
50	chromophobe renal cell carcinoma	10.3	EPCAM KRT7 KRT8

Graphical network of the top 20 diseases related to Craniopharyngioma:

Sources

Symptoms & Phenotypes for Craniopharyngioma

Human phenotypes related to Craniopharyngioma:

⁶⁰ ³³ (show all 47)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	abnormal hypothalamus morphology ⁶⁰ ³³	obligate (100%)	Obligate (100%)	HP:0012286
2	cerebral calcification ⁶⁰ ³³	hallmark (90%)	Very frequent (99-80%)	HP:0002514
3	neoplasm of the anterior pituitary ⁶⁰ ³³	hallmark (90%)	Very frequent (99-80%)	HP:0011750
4	enlarged pituitary gland ⁶⁰ ³³	hallmark (90%)	Very frequent (99-80%)	HP:0012505
5	intracranial cystic lesion ⁶⁰ ³³	hallmark (90%)	Very frequent (99-80%)	HP:0010576
6	obesity ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0001513
7	nausea and vomiting ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0002017
8	papilledema ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0001085
9	slow decrease in visual acuity ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0007924
10	headache ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0002315
11	abnormal visual field test ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0030588
12	pituitary hypothyroidism ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0008245
13	excessive daytime somnolence ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0001262
14	bitemporal hemianopia ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0030521
15	prolactin excess ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0000870
16	central diabetes insipidus ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0000863
17	progressive visual field defects ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0007987
18	central adrenal insufficiency ⁶⁰ ³³	frequent (33%)	Frequent (79-30%)	HP:0011734
19	hypogonadotrophic hypogonadism ³³	frequent (33%)		HP:0000044
20	hydrocephalus ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0000238
21	sleep apnea ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0010535
22	hearing impairment ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0000365
23	increased intracranial pressure ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0002516
24	type ii diabetes mellitus ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0005978
25	optic atrophy ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0000648
26	delayed puberty ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0000823
27	cerebral ischemia ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0002637
28	polyphagia ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0002591
29	increased susceptibility to fractures ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0002659
30	proportionate short stature ⁶⁰ ³³	occasional (7.5%)	Occasional (29-5%)	HP:0003508
31	intellectual disability ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0001249
32	seizures ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0001250
33	global developmental delay ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0001263
34	myocardial infarction ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0001658
35	postnatal growth retardation ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0008897
36	vertigo ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0002321
37	coma ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0001259
38	recurrent infections ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0002719
39	sudden loss of visual acuity ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0001117
40	abnormality of the nasal bone ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0010939
41	abnormality of the frontal bone ⁶⁰ ³³	very rare (1%)	Very rare (<4-1%)	HP:0430000
42	sleep disturbance ⁶⁰		Frequent (79-30%)
43	behavioral abnormality ⁶⁰		Very rare (<4-1%)
44	growth delay ⁶⁰		Occasional (29-5%)
45	hypogonadism ⁶⁰		Frequent (79-30%)
46	low gonadotropins (secondary hypogonadism) ⁶⁰		Frequent (79-30%)
47	hypopituitarism ⁶⁰		Very frequent (99-80%)

UMLS symptoms related to Craniopharyngioma:

visual disturbance

GenomeRNAi Phenotypes related to Craniopharyngioma according to GeneCards Suite gene sharing:

²⁷ (show all 37)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-101	10.14	GH1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-11	10.14	CTNNB1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-113	10.14	CTNNB1
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	10.14	GH1
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	10.14	POU1F1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-126	10.14	KRT8
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-130	10.14	GH1
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	10.14	APC
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-135	10.14	KRT7 KRT8 GH1 POU1F1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	10.14	POU1F1
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	10.14	POU1F1
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.14	GH1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10.14	GH1
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.14	APC CTNNB1
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-185	10.14	POU1F1
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	10.14	APC KRT7 KRT8
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-197	10.14	CTNNB1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	10.14	APC
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.14	GH1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	10.14	APC
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-4	10.14	POU1F1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	10.14	CTNNB1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	10.14	APC CTNNB1
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-54	10.14	GH1
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-6	10.14	KRT8
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	10.14	CTNNB1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.14	CTNNB1
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	10.14	APC KRT7 KRT8 CTNNB1
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-79	10.14	CTNNB1
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-82	10.14	POU1F1
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-96	10.14	GH1
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	10.14	POU1F1
33	Increased Nanog expression	GR00371-A-1	9.61	MKI67 PROP1 SP7 VEGFA
34	Increased Nanog expression	GR00371-A-2	9.61	VEGFA
35	Increased Nanog expression	GR00371-A-3	9.61	PROP1
36	Increased Nanog expression	GR00371-A-4	9.61	VEGFA
37	Increased Nanog expression	GR00371-A-5	9.61	PROP1 VEGFA

MGI Mouse Phenotypes related to Craniopharyngioma:

⁴⁷ (show all 20)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.45	APC BRAF CTNNB1 EPCAM GHRL GNRH1
2	endocrine/exocrine gland	MP:0005379	10.41	APC BRAF CTNNB1 EPCAM GHRL GNRH1
3	growth/size/body region	MP:0005378	10.4	APC BRAF CTNNB1 EPCAM GNRH1 IGF1
4	cellular	MP:0005384	10.33	APC BRAF CTNNB1 EPCAM IGF1 INS
5	immune system	MP:0005387	10.29	APC BRAF CTNNB1 EPCAM GNRH1 IGF1
6	hematopoietic system	MP:0005397	10.28	APC BRAF CTNNB1 EPCAM GNRH1 IGF1
7	digestive/alimentary	MP:0005381	10.27	APC BRAF CTNNB1 EPCAM GHRL GNRH1
8	nervous system	MP:0003631	10.21	APC BRAF CTNNB1 EPCAM GNRH1 IGF1
9	integument	MP:0010771	10.15	APC BRAF CTNNB1 GNRH1 IGF1 INS
10	craniofacial	MP:0005382	10.13	APC BRAF CTNNB1 KRT14 MMP20 POU1F1
11	hearing/vestibular/ear	MP:0005377	10.09	APC BRAF CTNNB1 IGF1 KRT14 KRT8
12	liver/biliary system	MP:0005370	10.08	APC BRAF CTNNB1 GNRH1 INS KRT8
13	normal	MP:0002873	10.07	APC BRAF CTNNB1 GHRL GNRH1 IGF1
14	neoplasm	MP:0002006	10.06	APC BRAF CTNNB1 GNRH1 IGF1 KRT14
15	reproductive system	MP:0005389	9.93	APC BRAF CTNNB1 GNRH1 IGF1 INS
16	no phenotypic analysis	MP:0003012	9.88	CTNNB1 EPCAM INS MKI67 TRH VEGFA
17	renal/urinary system	MP:0005367	9.86	APC BRAF CTNNB1 GNRH1 IGF1 INS
18	pigmentation	MP:0001186	9.72	APC BRAF CTNNB1 KRT14 POU1F1
19	respiratory system	MP:0005388	9.5	BRAF CTNNB1 IGF1 KRT14 PROP1 SP7
20	skeleton	MP:0005390	9.28	APC BRAF CTNNB1 GNRH1 IGF1 INS

Sources

Drugs & Therapeutics for Craniopharyngioma

Drugs for Craniopharyngioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

5754

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1

glucocorticoids

Phase 4,Phase 1

Hormones

Phase 4,Phase 3,Phase 2,Phase 1

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Hydrocortisone-17-butyrate

Phase 4

Hydrocortisone hemisuccinate

Phase 4

Anti-Inflammatory Agents

Phase 4,Phase 1

Hormone Antagonists

Phase 4,Phase 3,Phase 2,Phase 1

Anesthetics

Phase 4,Phase 3

Antineoplastic Agents, Hormonal

Phase 4,Phase 2,Phase 1,Not Applicable

Exenatide

Approved, Investigational

Phase 3,Phase 2,Phase 1

141758-74-9

15991534

Glucagon

Approved

Phase 3

16941-32-5

Diazoxide

Approved

Phase 3,Phase 2

364-98-7

3019

Ondansetron

Approved

Phase 3

99614-02-5

4595

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3,Phase 1

1177-87-3

Granisetron

Approved, Investigational

Phase 3

109889-09-0

3510

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3,Phase 1

50-02-2

5743

Cisplatin

Approved

Phase 3

15663-27-1

441203 84093 2767

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Donepezil

Approved

Phase 3,Phase 2,Early Phase 1

120014-06-4

3152

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Incretins

Phase 3,Phase 2,Phase 1

Glucagon-Like Peptide 1

Phase 3

Anti-Obesity Agents

Phase 3,Phase 2,Phase 1

Hypoglycemic Agents

Phase 3,Phase 2,Phase 1

Antihypertensive Agents

Phase 3,Phase 2

Vasodilator Agents

Phase 3,Phase 2

Peripheral Nervous System Agents

Phase 3,Phase 1

Gastrointestinal Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Emetics

Phase 3

BB 1101

Phase 3,Phase 1

Autonomic Agents

Phase 3,Phase 1

Antiemetics

Phase 3,Phase 1

Liver Extracts

Phase 3,Phase 1,Phase 2

Anesthetics, Intravenous

Phase 3

Cola

Phase 3,Phase 1

Central Nervous System Depressants

Phase 3,Phase 1

Narcotics

Phase 3

Anesthetics, General

Phase 3

Adjuvants, Anesthesia

Phase 3

Analgesics, Opioid

Phase 3

Analgesics

Phase 3

Cholinesterase Inhibitors

Phase 3,Phase 2,Early Phase 1

Nootropic Agents

Phase 3,Phase 2,Early Phase 1

Cholinergic Agents

Phase 3,Phase 2,Early Phase 1

Neurotransmitter Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Trioxsalen

Approved

Phase 2,Phase 1

3902-71-4

5585

Interventional clinical trials:

(show top 50) (show all 109)

#	Name	Status	NCT ID	Phase	Drugs
1	Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions	Unknown status	NCT02190994	Phase 4	Hydrocortisone;Prednisone
2	SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors	Unknown status	NCT00517959	Phase 3
3	Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy	Completed	NCT02860923	Phase 3	Exenatide;Placebo
4	Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions	Completed	NCT00306683	Phase 3	DIAZOXIDE
5	Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy	Completed	NCT01346267	Phase 3
6	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
7	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors	Completed	NCT00369785	Phase 3	donepezil hydrochloride;Placebo
8	Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity	Recruiting	NCT02664441	Phase 3	Exenatide;placebo
9	90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors	Recruiting	NCT02081768	Phase 3
10	Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery	Completed	NCT01964300	Phase 2
11	Hypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide Therapy	Completed	NCT00892073	Phase 2	Diazoxide;Metformin
12	Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor	Completed	NCT01484873	Phase 2	Exenatide
13	A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects	Completed	NCT00187226	Phase 2
14	An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury	Completed	NCT02063295	Phase 2	ZGN-440 sterile diluent;ZGN-440 for injectable suspension
15	Irinotecan in Treating Children With Refractory Solid Tumors	Completed	NCT00004078	Phase 2	irinotecan hydrochloride
16	Antineoplaston Therapy in Treating Children With Brain Tumors	Completed	NCT00003458	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
17	Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors	Completed	NCT00005952	Phase 1, Phase 2	temozolomide
18	Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors	Completed	NCT00003461	Phase 1, Phase 2
19	Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma	Completed	NCT00006102	Phase 2	becatecarin
20	Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors	Completed	NCT00005955	Phase 2	temozolomide
21	Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor	Completed	NCT00070161	Phase 2	donepezil hydrochloride
22	Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment	Completed	NCT00066248	Phase 2	cyproheptadine hydrochloride;megestrol acetate
23	A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection	Recruiting	NCT02792582	Phase 2
24	Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma	Recruiting	NCT03224767	Phase 2	Vemurafenib;Cobimetinib
25	Intranasal Oxytocin in Hypothalamic Obesity	Recruiting	NCT02849743	Phase 2	Syntocinon;Placebo (for Syntocinon)
26	Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors	Recruiting	NCT03194906	Phase 2	Memantine
27	Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma	Recruiting	NCT02367859	Phase 2	Dabrafenib;Trametinib
28	Methionine PET/CT Studies In Patients With Cancer	Recruiting	NCT00840047	Phase 2	Methionine
29	A Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical Resection	Active, not recruiting	NCT01419067	Phase 2	^1^8F-fluorodeoxyglucose;^1^1C-methionine
30	Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)	Active, not recruiting	NCT02842723	Phase 2
31	Effects of Exenatide on Hypothalamic Obesity	Active, not recruiting	NCT01061775	Phase 1, Phase 2	Exenatide
32	Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas	Active, not recruiting	NCT01966809	Phase 2	Photofrin photodynamic therapy.
33	Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors	Active, not recruiting	NCT00788125	Phase 1, Phase 2	carboplatin;dasatinib;etoposide phosphate;ifosfamide
34	Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy	Terminated	NCT01348607	Phase 2	methylphenidate hydrochloride;modafinil;placebo
35	Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors	Unknown status	NCT00002647	Phase 1	verteporfin
36	Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma	Unknown status	NCT00360854	Phase 1	erlotinib hydrochloride
37	Stereotactic Radiosurgery in Treating Patients With Brain Tumors	Completed	NCT00019578	Phase 1
38	ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors	Completed	NCT00946335	Phase 1	veliparib;temozolomide
39	RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma	Completed	NCT01119599	Phase 1	Gamma-Secretase Inhibitor RO4929097;Temozolomide
40	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma	Completed	NCT00363272	Phase 1	ispinesib
41	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors	Completed	NCT01076530	Phase 1	vorinostat;temozolomide
42	Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma	Completed	NCT00994500	Phase 1	vorinostat;bortezomib
43	Cilengitide in Treating Children With Refractory Primary Brain Tumors	Completed	NCT00063973	Phase 1	cilengitide
44	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors	Completed	NCT00052780	Phase 1	O6-benzylguanine;temozolomide
45	Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors	Completed	NCT00100880	Phase 1	lenalidomide
46	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	Completed	NCT00053963	Phase 1	romidepsin
47	Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors	Completed	NCT01682746	Phase 1	Photofrin (porfimer sodium) & photodynamic therapy.
48	O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors	Completed	NCT00003765	Phase 1	O6-benzylguanine;carmustine
49	SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors	Completed	NCT00015899	Phase 1	lonafarnib
50	A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors	Completed	NCT00784914	Phase 1	temsirolimus

Search NIH Clinical Center for Craniopharyngioma

Cochrane evidence based reviews: craniopharyngioma

Sources

Genetic Tests for Craniopharyngioma

Sources

Anatomical Context for Craniopharyngioma

MalaCards organs/tissues related to Craniopharyngioma:

⁴²

Brain, Pituitary, Hypothalamus, Bone, Testes, Liver, Spinal Cord

Sources

Publications for Craniopharyngioma

Articles related to Craniopharyngioma:

(show top 50) (show all 1460)

#	Title	Authors	Year
1	Pituitary Adenoma and Craniopharyngioma Collision Tumor: Diagnostic, Treatment Considerations, and Review of the Literature. ( 30326307 )	Snyder R...Mason RB	2019
2	Trans-eyebrow supraorbital keyhole approach in suprasellar and third ventricular craniopharyngioma surgery: the experience of 27 cases and a literature review. ( 30392089 )	Cai M...Hou B	2019
3	Management of hypothalamic disease in patients with craniopharyngioma. ( 30614015 )	Thompson CJ...Crowley RK	2019
4	Noninvasive molecular diagnosis of craniopharyngioma with MRI-based radiomics approach. ( 30616515 )	Chen X...Yu J	2019
5	Management of Craniopharyngioma. ( 30640850 )	Kili? M...Tanik C	2019
6	SHH pathway inhibition is protumourigenic in adamantinomatous craniopharyngioma. ( 30645190 )	Carreno G...Martinez-Barbera JP	2019
7	Growth hormone replacement therapy improves hypopituitarism-associated hypoxemia in a patient after craniopharyngioma surgery: A case report. ( 30653131 )	Qi W...Wu C	2019
8	Adipsic diabetes insipidus secondary to craniopharyngioma resection. ( 30709829 )	P?rez MA...Fl?rez Romero A	2019
9	Patterns of Care in Pediatric Craniopharyngioma: Outcomes Following Definitive Radiotherapy. ( 30711960 )	Hill TK...Zhang C	2019
10	Craniopharyngioma: 10 Selected Works That Provide Comprehensive and Valuable Insight into These Complex Tumors. ( 30716873 )	Pascual JM...Carrasco R	2019
11	In Reply to the Letter to the Editor "Craniopharyngioma: 10 Selected Works Which Provide Comprehensive and Valuable Insight into These Complex Tumors". ( 30716874 )	Jusue-Torres I...Germanwala AV	2019
12	Subfrontal Infrachiasmatic Approach to a Craniopharyngioma Resection: 2-Dimensional Operative Video. ( 30726971 )	Aldave G...Whitehead WE	2019
13	Efficacy of Direct Revascularization Surgery for Hemorrhagic Moyamoya Syndrome As a Late Complication of Cranial Irradiation for Childhood Craniopharyngioma. ( 30772161 )	Kato Y...Tominaga T	2019
14	Intrachiasmatic craniopharyngioma: Assessment of visual outcome with optical coherence tomography after complete surgical removal. ( 30775061 )	Gil-Simoes R...de Sola RG	2019
15	MANAGEMENT OF ENDOCRINE DISEASE: Childhood-onset Craniopharyngioma: state of the art of care in 2018. ( 30817319 )	M?ller HL	2019
16	Anterior cerebral artery rupture during extended endoscopic endonasal transsphenoidal approach for severely calcified craniopharyngioma. ( 30844531 )	Wang C...Ni S	2019
17	An ectopic recurrent craniopharyngioma of the temporal lobe: Case report and review of the literature. ( 30877004 )	Cai M...Guo Y	2019
18	Endoscopic Transsphenoidal Resection of Craniopharyngioma. ( 29404252 )	Liew K.Y....Waran V.	2018
19	Rare case of malignant craniopharyngioma reactive to adjunctive stereotactic radiotherapy and chemotherapy; Case report and review. ( 29933092 )	Nomura S....Kawamata T.	2018
20	Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma. ( 29681617 )	Yang J....Zhang H.	2018
21	The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study. ( 29388032 )	Chen M....Li S.T.	2018
22	Expanded Endoscopic Endonasal Resection of Retrochiasmatic Craniopharyngioma. ( 29404248 )	Davanzo J.R....Zacharia B.E.	2018
23	Childhood Craniopharyngioma: A 22-Year Challenging Follow-Up in a Single Center. ( 29959763 )	Tosta-Hernandez P.D.C....Spinola-Castro A.M.	2018
24	Micturition Disorders as the First Symptom of Multiple Pituitary Hormone Deficiency Caused by Craniopharyngioma. ( 29314378 )	Berk K....Korzeniecka-Kozerska A.	2018
25	Self- and informant-rated apathy in patients with childhood-onset craniopharyngioma. ( 29971569 )	Mehren A....MA1ller H.L.	2018
26	A Craniopharyngioma Associated With Elevated Cerebrospinal Fluid HCG Concentrations Misdiagnosed as a Germinoma. ( 29963005 )	Gu W....Mu Y.	2018
27	Extended Endoscopic Endonasal Approach for Suprasellar Craniopharyngioma. ( 29404249 )	Locatelli D....Castelnuovo P.	2018
28	Predicting parental distress among children newly diagnosed with craniopharyngioma. ( 29932288 )	Peterson R.K....Conklin H.M.	2018
29	Letter to the Editor Regarding &quot;Anatomic Dissection of Arachnoid Membranes Encircling the Pituitary Stalk on Fresh Non-Formalin-Fixed Specimens: Anatomoradiologic Correlations and Clinical Applications in Craniopharyngioma Surgery&quot;. ( 29232813 )	Kurucz P....Ganslandt O.	2018
30	Rathke's Cleft Cyst as Origin of a Pediatric Papillary Craniopharyngioma. ( 29520296 )	Schlaffer S.M....HAPlsken A.	2018
31	A novel endoscopic classification for craniopharyngioma based on its origin. ( 29977006 )	Tang B....Hong T.	2018
32	A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )	Lockemer H.E....Garg A.	2018
33	Characterization of the murine orthotopic adamantinomatous craniopharyngioma PDX model by MRI in correlation with histology. ( 29795641 )	HAPlsken A....BAouerle T.	2018
34	Radiation therapy rather than prior surgery reduces extent of resection during endonasal endoscopic reoperation for craniopharyngioma. ( 29802559 )	Younus I....Schwartz T.H.	2018
35	Chemical meningitis from a leaking craniopharyngioma: a case report. ( 29663082 )	Hakizimana D....Fugleholm K.	2018
36	The development of hypothalamic obesity in craniopharyngioma patients: A risk factor analysis in a well-defined cohort. ( 29314661 )	van Iersel L....van Santen H.M.	2018
37	Fusiform dilatation of the internal carotid artery following childhood craniopharyngioma resection treated by endovascular flow diversion-A case report and literature review. ( 29805079 )	Reynolds M.R....Dion J.E.	2018
38	Clinical outcomes of childhood craniopharyngioma: can we do better? ( 29934877 )	Webb S.M.	2018
39	Combined endoscopic approach in the management of suprasellar craniopharyngioma. ( 29435609 )	Deopujari C.E....Shaikh S.	2018
40	Interventions for the treatment of craniopharyngioma-related hypothalamic obesity: a systematic review. ( 29945001 )	Ni W....Shi X.	2018
41	Endoscopic Endonasal Resection of Retrochiasmatic Craniopharyngioma with Fascia Lata Button and Nasoseptal Flap Reconstruction. ( 29404247 )	Kshettry V.R....Evans J.J.	2018
42	Abscess inside craniopharyngioma: diagnostic and management implications. ( 29431099 )	Bhaisora K.S....Lal H.	2018
43	Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review. ( 29901583 )	Nagafuji H....Saito K.	2018
44	Letter to the Editor. The role of preoperative MRI in predicting craniopharyngioma behavior. ( 29726783 )	Prieto R....Barrios L.	2018
45	Craniopharyngioma - a chronic disease. ( 29442345 )	MA1ller H.	2018
46	Intraventricular recurrence of a craniopharyngioma: case report. ( 29957141 )	Renfrow J.J....Couture D.E.	2018
47	Extended Endoscopic Endonasal Approach for Craniopharyngioma Removal. ( 29404250 )	Messerer M....Daniel R.T.	2018
48	Phosphorus-32 interstitial radiotherapy for recurrent craniopharyngioma: Expressions of vascular endothelial growth factor and its receptor-2 and imaging features of tumors are associated with tumor radiosensitivity. ( 29952957 )	Hu C....Yu X.	2018
49	Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. ( 29701552 )	Himes B.T....Uhm J.H.	2018
50	Limits of endoscopic endonasal surgery for craniopharyngioma. ( 29378389 )	Hardesty D.A....Prevedello D.M.	2018

Sources

Genes for Craniopharyngioma

Genes related to Craniopharyngioma (3 elite genes):

(show all 21)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	CTNNB1	Catenin Beta 1	Protein Coding	413.09	Causative somatic mutation ⁶⁰ Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Variants (show sections)	15891929 20128632 15221941 (more) 16596257 18540944 18318590 15980970 12466115 14578169 20179436
2	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	400	Pathogenic ⁶
3	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	357.36	Causative somatic mutation ⁶⁰ GeneCards inferred via : Publications (show sections)
4	IGF1	Insulin Like Growth Factor 1	Protein Coding	28.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	10848878 15817911 10372703 (more) 1719442 10469014 8314202 16000560
5	KRT8	Keratin 8	Protein Coding	26.04	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	12296753 11770017
6	KRT14	Keratin 14	Protein Coding	23.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	11770017
7	PRL	Prolactin	Protein Coding	22.76	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶	17556861 10659562 7627336 (more) 8098858 1955511
8	PROP1	PROP Paired-Like Homeobox 1	Protein Coding	21.64	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶	11822586
9	INS	Insulin	Protein Coding	21.37	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	21.32	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	TRH	Thyrotropin Releasing Hormone	Protein Coding	21.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	MKI67	Marker Of Proliferation Ki-67	Protein Coding	20.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	GNRH1	Gonadotropin Releasing Hormone 1	Protein Coding	20.56	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	EPCAM	Epithelial Cell Adhesion Molecule	Protein Coding	20.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
15	KRT7	Keratin 7	Protein Coding	20.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
16	GH1	Growth Hormone 1	Protein Coding	20.13	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶	15251557 8729528 10659562 (more) 12510977 8879991 8098858 11735238 12807508 10890195
17	POU1F1	POU Class 1 Homeobox 1	Protein Coding	20.05	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	SP7	Sp7 Transcription Factor	Protein Coding	20.02	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
19	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	19.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	MMP20	Matrix Metallopeptidase 20	Protein Coding	19.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	MCM6	Minichromosome Maintenance Complex Component 6	Protein Coding	19.76	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	17294730 17410335

Sources

Variations for Craniopharyngioma

ClinVar genetic disease variations for Craniopharyngioma:

⁶ (show all 45)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	BMPR1A	NM_004329.2(BMPR1A): c.499A> T (p.Met167Leu)	single nucleotide variant	Uncertain significance	rs200951235	GRCh37	Chromosome 10, 88659852: 88659852
2	BMPR1A	NM_004329.2(BMPR1A): c.499A> T (p.Met167Leu)	single nucleotide variant	Uncertain significance	rs200951235	GRCh38	Chromosome 10, 86900095: 86900095
3	PTCH1	NM_000264.4(PTCH1): c.113G> A (p.Gly38Glu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs143494325	GRCh37	Chromosome 9, 98270531: 98270531
4	PTCH1	NM_000264.4(PTCH1): c.113G> A (p.Gly38Glu)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs143494325	GRCh38	Chromosome 9, 95508249: 95508249
5	SMARCA4	NM_001128849.1(SMARCA4): c.442G> A (p.Gly148Arg)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs138689221	GRCh38	Chromosome 19, 10986275: 10986275
6	SMARCA4	NM_001128849.1(SMARCA4): c.442G> A (p.Gly148Arg)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs138689221	GRCh37	Chromosome 19, 11096951: 11096951
7	CTNNB1	NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28931588	GRCh37	Chromosome 3, 41266097: 41266097
8	CTNNB1	NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs28931588	GRCh38	Chromosome 3, 41224606: 41224606
9	CTNNB1	NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28931589	GRCh37	Chromosome 3, 41266104: 41266104
10	CTNNB1	NM_001904.3(CTNNB1): c.101G> T (p.Gly34Val)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28931589	GRCh38	Chromosome 3, 41224613: 41224613
11	BRCA1	NM_007294.3(BRCA1): c.5123C> T (p.Ala1708Val)	single nucleotide variant	Uncertain significance	rs28897696	GRCh37	Chromosome 17, 41215920: 41215920
12	BRCA1	NM_007294.3(BRCA1): c.5123C> T (p.Ala1708Val)	single nucleotide variant	Uncertain significance	rs28897696	GRCh38	Chromosome 17, 43063903: 43063903
13	PTPN11	NM_002834.4(PTPN11): c.925A> G (p.Ile309Val)	single nucleotide variant	Benign	rs201787206	GRCh37	Chromosome 12, 112915526: 112915526
14	PTPN11	NM_002834.4(PTPN11): c.925A> G (p.Ile309Val)	single nucleotide variant	Benign	rs201787206	GRCh38	Chromosome 12, 112477722: 112477722
15	TSC1	NM_000368.4(TSC1): c.1231C> A (p.Leu411Ile)	single nucleotide variant	Uncertain significance	rs397514840	GRCh37	Chromosome 9, 135785990: 135785990
16	TSC1	NM_000368.4(TSC1): c.1231C> A (p.Leu411Ile)	single nucleotide variant	Uncertain significance	rs397514840	GRCh38	Chromosome 9, 132910603: 132910603
17	TSC2	NM_000548.3(TSC2): c.3803G> A (p.Arg1268His)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs200577441	GRCh37	Chromosome 16, 2131788: 2131788
18	TSC2	NM_000548.3(TSC2): c.3803G> A (p.Arg1268His)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs200577441	GRCh38	Chromosome 16, 2081787: 2081787
19	APC	NM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs)	deletion	Pathogenic	rs587779352	GRCh37	Chromosome 5, 112174474: 112174478
20	APC	NM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs)	deletion	Pathogenic	rs587779352	GRCh38	Chromosome 5, 112838777: 112838781
21	CDH1	NM_004360.5(CDH1): c.1225T> C (p.Trp409Arg)	single nucleotide variant	Uncertain significance	rs587778176	GRCh37	Chromosome 16, 68847303: 68847303
22	CDH1	NM_004360.5(CDH1): c.1225T> C (p.Trp409Arg)	single nucleotide variant	Uncertain significance	rs587778176	GRCh38	Chromosome 16, 68813400: 68813400
23	TSC2	NM_000548.3(TSC2): c.3846_3855delCTGCCAAGGAinsG (p.Ser1282_Gly1285delinsArg)	indel	Conflicting interpretations of pathogenicity	rs587778732	GRCh38	Chromosome 16, 2082467: 2082476
24	TSC2	NM_000548.3(TSC2): c.3846_3855delCTGCCAAGGAinsG (p.Ser1282_Gly1285delinsArg)	indel	Conflicting interpretations of pathogenicity	rs587778732	GRCh37	Chromosome 16, 2132468: 2132477
25	SUFU	NM_016169.3(SUFU): c.839G> A (p.Arg280Gln)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs145704867	GRCh37	Chromosome 10, 104356979: 104356979
26	SUFU	NM_016169.3(SUFU): c.839G> A (p.Arg280Gln)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs145704867	GRCh38	Chromosome 10, 102597222: 102597222
27	CTNNB1	NM_001904.3(CTNNB1): c.100G> A (p.Gly34Arg)	single nucleotide variant	Likely pathogenic	rs121913399	GRCh37	Chromosome 3, 41266103: 41266103
28	CTNNB1	NM_001904.3(CTNNB1): c.100G> A (p.Gly34Arg)	single nucleotide variant	Likely pathogenic	rs121913399	GRCh38	Chromosome 3, 41224612: 41224612
29	CTNNB1	NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg)	single nucleotide variant	Likely pathogenic	rs121913399	GRCh37	Chromosome 3, 41266103: 41266103
30	CTNNB1	NM_001904.3(CTNNB1): c.100G> C (p.Gly34Arg)	single nucleotide variant	Likely pathogenic	rs121913399	GRCh38	Chromosome 3, 41224612: 41224612
31	TSC1	NM_000368.4(TSC1): c.1355G> C (p.Gly452Ala)	single nucleotide variant	Uncertain significance	rs371093730	GRCh37	Chromosome 9, 135782201: 135782201
32	TSC1	NM_000368.4(TSC1): c.1355G> C (p.Gly452Ala)	single nucleotide variant	Uncertain significance	rs371093730	GRCh38	Chromosome 9, 132906814: 132906814
33	TSC2	NM_000548.3(TSC2): c.3038A> G (p.Asp1013Gly)	single nucleotide variant	Uncertain significance	rs1060500961	GRCh37	Chromosome 16, 2129104: 2129104
34	TSC2	NM_000548.3(TSC2): c.3038A> G (p.Asp1013Gly)	single nucleotide variant	Uncertain significance	rs1060500961	GRCh38	Chromosome 16, 2079103: 2079103
35	NF1	NM_000267.3(NF1): c.4773G> A (p.Arg1591=)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs1555533268	GRCh37	Chromosome 17, 29652838: 29652838
36	NF1	NM_000267.3(NF1): c.4773G> A (p.Arg1591=)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs1555533268	GRCh38	Chromosome 17, 31325820: 31325820
37	MSH6	NM_000179.2(MSH6): c.1657A> C (p.Thr553Pro)	single nucleotide variant	Uncertain significance		GRCh37	Chromosome 2, 48026779: 48026779
38	MSH6	NM_000179.2(MSH6): c.1657A> C (p.Thr553Pro)	single nucleotide variant	Uncertain significance		GRCh38	Chromosome 2, 47799640: 47799640
39	PHOX2B	NM_003924.3(PHOX2B): c.556G> A (p.Glu186Lys)	single nucleotide variant	Uncertain significance		GRCh38	Chromosome 4, 41746196: 41746196
40	PHOX2B	NM_003924.3(PHOX2B): c.556G> A (p.Glu186Lys)	single nucleotide variant	Uncertain significance		GRCh37	Chromosome 4, 41748213: 41748213
41	PTCH1	NM_000264.4(PTCH1): c.203G> A (p.Gly68Glu)	single nucleotide variant	Uncertain significance		GRCh38	Chromosome 9, 95506598: 95506598
42	PTCH1	NM_000264.4(PTCH1): c.203G> A (p.Gly68Glu)	single nucleotide variant	Uncertain significance		GRCh37	Chromosome 9, 98268880: 98268880
43	KRAS	NM_004985.4: c.547_552delACAAAG	deletion	Uncertain significance		GRCh38	Chromosome 12, 25209815: 25209820
44	KRAS	NM_004985.4: c.547_552delACAAAG	deletion	Uncertain significance		GRCh37	Chromosome 12, 25362744: 25362749
45	ERCC2	NM_000400.3: c.1367_1369delTCA	undetermined variant	Likely pathogenic		GRCh38	Chromosome 19, 45357482: 45357484

Cosmic variations for Craniopharyngioma:

⁹ (show all 22)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM5672	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.94G>A	p.D32N	3:41224606-41224606
2	COSM5679	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.110C>G	p.S37C	3:41224622-41224622
3	COSM5669	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.98C>T	p.S33F	3:41224610-41224610
4	COSM5668	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.94G>C	p.D32H	3:41224606-41224606
5	COSM5684	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.100G>C	p.G34R	3:41224612-41224612
6	COSM5662	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.110C>T	p.S37F	3:41224622-41224622
7	COSM5674	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.104T>G	p.I35S	3:41224616-41224616
8	COSM5676	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.122C>T	p.T41I	3:41224634-41224634
9	COSM5683	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.97T>G	p.S33A	3:41224609-41224609
10	COSM5682	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.97T>C	p.S33P	3:41224609-41224609
11	COSM5677	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.98C>G	p.S33C	3:41224610-41224610
12	COSM5691	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.95A>T	p.D32V	3:41224607-41224607
13	COSM5681	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.95A>G	p.D32G	3:41224607-41224607
14	COSM5663	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.133T>C	p.S45P	3:41224645-41224645
15	COSM5664	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.121A>G	p.T41A	3:41224633-41224633
16	COSM5661	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.94G>T	p.D32Y	3:41224606-41224606
17	COSM5673	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.98C>A	p.S33Y	3:41224610-41224610
18	COSM5701	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.122C>G	p.T41S	3:41224634-41224634
19	COSM5758	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.127G>A	p.A43T	3:41224639-41224639
20	COSM5687	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.109T>C	p.S37P	3:41224621-41224621
21	COSM5686	CTNNB1	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.100G>A	p.G34R	3:41224612-41224612
22	COSM476	BRAF	pituitary,craniopharyngeal duct,craniopharyngioma,adamantinomatous	c.1799T>A	p.V600E	7:140753336-140753336

Sources

Expression for Craniopharyngioma

Search GEO for disease gene expression data for Craniopharyngioma.

Sources

Pathways for Craniopharyngioma

Pathways related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 19)

#	Super pathways	Score	Top Affiliating Genes
1	Nanog in Mammalian ESC Pluripotency ⁶⁵ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁵ eNOS Signaling ⁶⁵ GSK3 Signaling ⁶⁵	13.07	APC BRAF CTNNB1 GH1 GNRH1 IGF1
2	Pathways in cancer ³⁸	12.68	APC BRAF CTNNB1 IGF1 VEGFA
3	Ras signaling pathway ³⁸ Show member pathways Rap1 signaling pathway ³⁸	12.55	BRAF CTNNB1 IGF1 INS VEGFA
4	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.54	APC BRAF CTNNB1 IGF1 INS VEGFA
5	mTOR signaling pathway (KEGG) ⁶⁶ Show member pathways mTOR signaling pathway ³⁸	12.35	APC BRAF IGF1 INS
6	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.33	APC CTNNB1 GH1 IGF1 INS PRL
7	Proteoglycans in cancer ³⁸	12.1	BRAF CTNNB1 IGF1 VEGFA
8	Colorectal Cancer Metastasis ⁶⁵	11.98	APC BRAF CTNNB1 VEGFA
9	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	11.93	APC BRAF CTNNB1 GH1 GNRH1 IGF1
10	Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁶	11.83	EPCAM IGF1 INS VEGFA
11	Adipogenesis ¹	11.79	CTNNB1 GH1 IGF1 INS
12	HIF-1 signaling pathway ³⁸	11.75	IGF1 INS VEGFA
13	Corticotropin-releasing hormone signaling pathway ¹	11.71	BRAF CTNNB1 KRT14
14	Glucocorticoid receptor regulatory network ¹	11.64	KRT14 POU1F1 PRL
15	Glioblastoma Multiforme ⁶⁵	11.6	APC BRAF CTNNB1 IGF1
16	Primary Focal Segmental Glomerulosclerosis FSGS ¹	11.58	CTNNB1 KRT8 MKI67
17	Endochondral Ossification ¹	11.51	GH1 IGF1 VEGFA
18	Differentiation Pathway ¹	11.29	IGF1 INS VEGFA
19	Peptide hormone metabolism ⁶⁷ Show member pathways Glycoprotein hormones ⁶⁷ Insulin processing ⁶⁷ Metabolism of Angiotensinogen to Angiotensins ⁶⁷ Peptide hormone biosynthesis ⁶⁷ Synthesis, secretion, and deacylation of Ghrelin ⁶⁷	11.28	CTNNB1 GH1 GHRL IGF1 INS

Sources

GO Terms for Craniopharyngioma

Cellular components related to Craniopharyngioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.97	GH1 GHRL GNRH1 IGF1 INS MMP20
2	extracellular region	GO:0005576	9.97	GH1 GHRL GNRH1 IGF1 INS MMP20
3	keratin filament	GO:0045095	9.61	KRT14 KRT7 KRT8
4	secretory granule	GO:0030141	9.46	TRH VEGFA
5	beta-catenin destruction complex	GO:0030877	9.4	APC CTNNB1
6	cell periphery	GO:0071944	9.33	CTNNB1 KRT14 KRT8
7	Wnt signalosome	GO:1990909	9.26	APC CTNNB1
8	lateral plasma membrane	GO:0016328	9.13	APC CTNNB1 EPCAM
9	endosome lumen	GO:0031904	8.8	GH1 INS PRL

Biological processes related to Craniopharyngioma according to GeneCards Suite gene sharing:

(show all 22)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	9.91	BRAF CTNNB1 IGF1 INS VEGFA
2	positive regulation of cell migration	GO:0030335	9.87	APC IGF1 INS VEGFA
3	positive regulation of cold-induced thermogenesis	GO:0120162	9.78	APC GHRL VEGFA
4	positive regulation of peptidyl-tyrosine phosphorylation	GO:0050731	9.76	GH1 IGF1 VEGFA
5	positive regulation of phosphatidylinositol 3-kinase signaling	GO:0014068	9.72	GH1 IGF1 INS
6	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.7	GH1 IGF1 VEGFA
7	negative regulation of apoptotic process	GO:0043066	9.7	BRAF CTNNB1 GHRL GNRH1 IGF1 PROP1
8	response to nutrient levels	GO:0031667	9.63	GH1 GHRL PRL
9	JAK-STAT cascade involved in growth hormone signaling pathway	GO:0060397	9.6	GH1 PRL
10	positive regulation of insulin-like growth factor receptor signaling pathway	GO:0043568	9.59	GH1 IGF1
11	positive regulation of growth	GO:0045927	9.58	GH1 GHRL
12	adenohypophysis development	GO:0021984	9.54	POU1F1 PROP1
13	positive regulation of multicellular organism growth	GO:0040018	9.5	GH1 GHRL POU1F1
14	positive regulation of cell proliferation	GO:0008284	9.5	CTNNB1 EPCAM IGF1 INS POU1F1 PRL
15	positive regulation of epithelial cell proliferation	GO:0050679	9.49	IGF1 VEGFA
16	negative regulation of feeding behavior	GO:2000252	9.43	INS TRH
17	cell fate specification	GO:0001708	9.43	APC CTNNB1 POU1F1
18	positive regulation of glucose transmembrane transport	GO:0010828	9.4	BRAF GH1
19	somatotropin secreting cell differentiation	GO:0060126	9.37	POU1F1 PROP1
20	ovulation cycle	GO:0042698	9.26	GNRH1
21	regulation of signaling receptor activity	GO:0010469	9.23	GH1 GHRL GNRH1 IGF1 INS PRL
22	positive regulation of transcription by RNA polymerase II	GO:0045944	10.02	CTNNB1 EPCAM IGF1 POU1F1 PROP1 SP7

Molecular functions related to Craniopharyngioma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	hormone activity	GO:0005179	9.17	GH1 GHRL GNRH1 IGF1 INS PRL
2	prolactin receptor binding	GO:0005148	8.96	GH1 PRL

Sources

Sources for Craniopharyngioma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia